natgillin/translations-raw huggingface dataset:
Treatment of adults, children and adolescents (2 - 18 years) who do not have sufficient antibodies (Flebogamma DIF is used as replacement therapy).
Koristi se u terapiji odraslih, djece i adolescenata (2 - 18 godina) koji nemaju dovoljno protutijela (Flebogamma DIF služi kao nadomjesna terapija).
Instructions for handling and disposal
Upute za rukovanje i zbrinjavanje
Immunoglobulins are excreted into human milk.
Imunoglobulini se izlučuju u majčino mlijeko.
Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.
Prema kliničkim iskustvima s primjenom imunoglobulina ne treba očekivati štetne učinke na tijek trudnoće ili na fetus i novorođenče.
● maculopathy (illness of the macula, in the retina of the eyes)
● makulopatija (bolest makule, u mrežnici oka)
Each ml of this medicinal product contains 50 mg of sorbitol.
Svaki ml ovog lijeka sadrži 50 mg sorbitola.
• in case of high rate of infusion
• u slučaju visoke brzine infuzije
In patients receiving IVIg, there have been some reports of acute non-cardiogenic pulmonary oedema [Transfusion Related Acute Lung Injury (TRALI)].
U bolesnika koji su primali i.v. Ig bilo je zabilježeno nekoliko slučajeva akutnog nekardiogenog plućnog edema (akutno oštećenje pluća povezano s transfuzijom [engl.
In case of rubella, mumps and varicella a period of up to 3 months should elapse after receiving this medicine and before receiving these vaccines.
U slučaju cjepiva protiv rubeole, zaušnjaka i vodenih kozica, nakon primanja ovog lijeka treba proteći do 3 mjeseca prije cijepljenja ovim cjepivima.
• Cases of temporary non-infective meningitis (which signs are headache, fear or intolerance of light, stiff neck).
• privremeni neinfektivni meningitis (čiji su znakovi glavobolja, strah ili nepodnošenje svjetlosti, ukočeni vrat)
Depending on how comfortable you feel, your doctor may then gradually increase the infusion rate (up to 0.08 ml/kg/min).
Ovisno o tome kako se osjećate, Vaš liječnik može postupno povećati brzinu infuzije (do 0,08 ml/kg/min).
• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a rare and progressive disease causing limb weakness, numbness, pain and fatigue.
• kronična upalna demijelinizacijska poliradikuloneuropatija, rijetka i progresivna bolest koja uzrokuje slabost udova, utrnulost, bol i umor
• careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded,
• pažljiv izbor davatelja krvi i plazme kako bi se isključili potencijalno rizični davatelji
The dose that you will be given will depend on your illness and body weight and will be worked out by your doctor (please see section “Instructions for healthcare professionals” given at the end of this leaflet).
Doza koju ćete primiti ovisi o Vašoj bolesti i tjelesnoj težini što će izračunati Vaš liječnik (vidjeti dio
INFORMATION IN BRAILLE Justification for not including Braille accepted
Prihvaćeno obrazloženje za nenavođenje Brailleovog pisma
Therefore patients receiving measles vaccine should have their antibody status checked.
Prema tome, bolesnicima koji se cijepe protiv ospica treba provjeriti status protutijela.
• if you are having Flebogamma DIF for the first time, or it has been switched from an alternative human normal immunoglobulin (IVIg) product, or it is a long time since your last infusion (e.g. several weeks).
• ako primate lijek Flebogamma DIF prvi put ili ste do tada primali drugi lijek koji sadrži ljudski imunoglobulin ili ako je prošlo mnogo vremena od prethodne infuzije (npr. nekoliko tjedana).
How to store Flebogamma DIF Contents of the pack and other information
Kako čuvati lijek Flebogamma DIF Sadržaj pakiranja i druge informacije
Side effects may be reduced by switching to Flebogamma DIF 50 mg/ml.
Nuspojave se mogu smanjiti prijelazom na lijek Flebogamma DIF 50 mg/ml.
Human normal immunoglobulin is immediately and completely bioavailable in the recipient's circulation after intravenous administration.
Normalni ljudski imunoglobulin je nakon intravenske primjene odmah i u potpunosti bioraspoloživ u cirkulaciji primatelja.
• (very rarely) thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses
• (vrlo rijetko) tromboembolijske reakcije kao što su infarkt miokarda, moždani udar, plućna embolija, duboka venska tromboza
The dose interval when steady state has been reached varies from 3 - 4 weeks.
Za održavanje postignutog stanja dinamičke ravnoteže, interval između doziranja varira od 3 do 4 tjedna.
• blood volume decrease
• smanjeni volumen krvi
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČ BIOLOŠKE DJELATNE TVARI I PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE
This medicinal product contains less than 29,41 mg sodium per vial of 400 ml, equivalent to 1.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Ovaj lijek sadrži manje od 29,41 mg natrija po bočici od 400 ml, što odgovara 1,5% maksimalnog dnevnog unosa od 2 g natrija prema preporukama SZO-a za odraslu osobu.
The dose required to achieve a trough level of IgG of 6 g/l is of the order of 0.2 - 0.8 g/kg/month.
Doza potrebna za postizanje najniže razine IgG-a od 6 g/l iznosi 0,2 - 0,8 g/kg na mjesec.
Information on overdose in children has not been established with Flebogamma DIF.
Ne postoje podaci o predoziranju u djece za lijek Flebogamma DIF.
If you get more Flebogamma DIF than you should, your body may take on too much fluid.
Ako ste primili više lijeka Flebogamma DIF nego što ste trebali, u organizmu može nastati suvišak tekućine.
0.4 g/kg/day over 5 days (possible repeat of dosing in case of relapse).
Doza od 0,4 g/kg na dan tijekom 5 dana (u slučaju recidiva doziranje se može ponoviti).
One ml contains 50 mg of D-sorbitol.
Jedan ml lijeka sadrži 50 mg D-sorbitola.
• Patients with Primary Immunodeficiency Syndromes (PID), an inborn lack of antibodies (group 1)
• bolesnici sa sindromima primarne imunodeficijencije, urođenim nedostatkom protutijela (skupina 1)
Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded.
Usprkos ovim mjerama, pri primjeni lijekova proizvedenih iz ljudske krvi ili plazme, ne može se potpuno isključiti mogućnost prijenosa infekcije.
Flebogamma DIF is given by injection into your veins (intravenous administration).
Flebogamma DIF se daje injekcijom u vene (intravenska primjena).
• infusion site reactions (erythema, extravasation, inflammation, pain)
• reakcije na mjestu infuzije (eritem, ekstravazacija, upala, bol)
For intravenous use.
Za intravensku primjenu.
Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded.
Usprkos tome, pri primjeni lijekova proizvedenih iz ljudske krvi ili plazme, ne može se potpuno isključiti mogućnost prijenosa infektivnih agensa.
Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D, may interfere with some serological tests for red cell antibodies for example the direct antiglobulin test (DAT, direct Coomb's test).
Pasivno prenesena protutijela protiv eritrocitnih antigena, npr. A, B, D, mogu interferirati s nekim serološkim testovima na protutijela na crvene krvne stanice, primjerice s izravnim antiglobulinskim testom (DAT, izravni Coombsov test).
Replacement therapy:
Nadomjesna terapija:
As the dosage for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions, the dosage in children is not considered to be different to that of adults.
Budući da doziranje za svaku indikaciju ovisi o tjelesnoj težini i prilagođava se kliničkom ishodu gore navedenih stanja, doziranje u djece i adolescenata (2 - 18 godina) ne razlikuje se od doziranja u odraslih bolesnika.
0.4 g/kg/d on day 1, possibly repeated once within 3 days for 2 - 5 days
0,4 g/kg/d prvog dana, može se ponoviti još jednom unutar 3 dana tijekom 2 - 5 dana
Do not use Flebogamma DIF if you notice that the solution is cloudy or has deposits.
Ne koristite lijek Flebogamma DIF ako primijetite da je otopina mutna ili sadrži krute čestice.
Transfusion related acute lung injury (TRALI)
Transfusion Related Acute Lung Injury,
For intravenous use
Za intravensku primjenu
0.4 g/kg/d for 5 days
0,4 g/kg/d tijekom 5 dana
You must make up the infusion in exactly the way you have been shown in order to stop germs getting in. You must never self-administer it alone; a responsible adult must be always present.
Ne smijete nikad primijeniti lijek kad ste sami; s Vama uvijek mora biti odgovorna odrasla osoba.
Treatment of adults, children and adolescents (2 - 18 years) with certain autoimmune disorders (immunomodulation).
Koristi se u terapiji odraslih, djece i adolescenata (2 - 18 godina) koji imaju određene autoimune poremećaje (imunomodulacija).
• cases of Transfusion Related Acute Lung Injury (TRALI)
• slučajevi akutnog oštećenja pluća povezanog s transfuzijom (TRALI).
Flebogamma DIF is a solution for infusion.
Flebogamma DIF je otopina za infuziju.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Instituto Grifols, S.A.
11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Instituto Grifols, S.A.
In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic medicinal products or age over 65.
U većini slučajeva u tih su bolesnika identificirani čimbenici rizika kao što su to postojeća bubrežna insuficijencija, šećerna bolest, hipovolemija, pretilost, istodobna terapija nefrotoksičnim lijekovima ili dob iznad
If the patient tolerates the infusion well, additional increments of 0.02 ml/kg/min may be made at 30-minute intervals up to a maximum of 0.08 ml/kg/min.
Ako bolesnik dobro podnosi infuziju, brzinu je moguće povećavati za po 0,02 ml/kg/min svakih 30 minuta do maksimalnih 0,08 ml/kg/min.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped hepatitis A and parvovirus B19 viruses.
Navedene mjere smatraju se učinkovitima za viruse s ovojnicom kao što su virus humane imunodeficijencije (HIV), virus hepatitisa B (HBV) i virus hepatitisa C (HCV) i za viruse bez ovojnice kao što su virus hepatitisa A i parvovirus B19.
Discontinuation of IVIg treatment has resulted in remission of AMS within several days without sequelae.
Ig terapije rezultirao je remisijom AMS-a unutar nekoliko dana bez posljedica.
Replacement therapy: Primary immunodeficiency syndromes
Nadomjesna terapija kod sindroma primarnih imunodeficijencija
Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.
Prema kliničkim iskustvima s primjenom imunoglobulina ne treba očekivati štetne učinke na plodnost.
• Thromboembolic reactions such as myocardial infarction (tight band around the chest with feeling like your heart is beating too fast), stroke (muscle weakness in the face, arm, or leg, trouble speaking or understanding others who are speaking), pulmonary embolism (shortness of breath, chest pain and fatigue), deep vein thromboses (pain and swelling in an extremity).
• tromboembolijske reakcije kao što su infarkt miokarda (stezanje u prsima s osjećajem prebrzog rada srca), moždani udar (slabost mišića lica, ruke ili noge, otežan govor ili razumijevanje govora), plućna embolija (nedostatak daha, bol u prsnom košu i umor), duboka venska tromboza (bolovi i oticanje udova)
Pack size of 1 vial.
Veličina pakiranja je 1 bočica.
Indication
Indikacija
The safety results for 29 paediatric patients (those ≤ 17 years old) included in the PID studies were evaluated.
Procijenjeni su sigurnosni rezultati za 29 pedijatrijskih bolesnika (onih u dobi
Aseptic meningitis syndrome has been reported to occur in association with IVIg treatment.
Prijavljena je pojava sindroma aseptičkog meningitisa povezana s i.v. Ig terapijom.
• 0.4 g/kg given daily for two to five days.
• 0,4 g/kg primijenjeno svakodnevno tijekom dva do pet dana.
SPECIAL STORAGE CONDITIONS Do not store above 30 ºC.
POSEBNE MJERE ČUVANJA Ne čuvati na temperaturi iznad 30 ºC.
In babies and young children (aged 0 - 2 years) hereditary fructose intolerance may not yet be diagnosed and may be fatal, thus, they must not receive this medicine (see special warnings about excipients at the end of this section).
Dojenčad i mala djeca (u dobi od 0 - 2 godine), u kojih nasljedno nepodnošenje fruktoze vjerojatno još nije utvrđeno i moglo bi biti smrtonosno, ne smiju primati ovaj lijek (vidjeti posebna upozorenja o pomoćnim tvarima na kraju ovog dijela).
• Primary immune thrombocytopenia (ITP), a condition where the number of platelets in the blood stream is greatly reduced.
• primarna imunotrombocitopenija (ITP), stanje u kojem je broj trombocita u krvi znatno snižen.
● bronchitis
• bronhitis
Flebogamma DIF 100 mg/ml is contraindicated in children aged 0 to 2 years (see section 4.3).
Lijek Flebogamma DIF 100 mg/ml kontraindiciran je u djece u dobi od 0 do 2 godine (vidjeti dio 4.3).
Immunomodulation in adults, children and adolescents (2 - 18 years) in: - Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count - Guillain Barré syndrome - Kawasaki disease (in conjunction with acetylsalicylic acid; see 4.2) - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) - Multifocal motor neuropathy (MMN)
Imunomodulacija odraslih, djece i adolescenata (2 - 18 godina) kod: - primarne imunotrombocitopenije (ITP) u bolesnika s visokim rizikom od pojave krvarenja ili prije kirurškog zahvata u svrhu korekcije broja trombocita - Guillain-Barréovog sindroma - Kawasakijeve bolesti (zajedno s acetilsalicilatnom kiselinom, vidjeti dio 4.2) - kronične upalne demijelinizacijske poliradikuloneuropatije - multifokalne motorne neuropatije.
Patients with selective IgA deficiency who developed antibodies to IgA, as administering an IgA-containing product can result in anaphylaxis.
Bolesnici sa selektivnim nedostatkom IgA koji su razvili protutijela na IgA, jer primjena lijeka koji sadrži IgA može rezultirati anafilaksijom.
 Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Drugi lijekovi i Flebogamma DIF  Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli bilo koje druge lijekove.
• Cases of transfusion related acute lung injury (TRALI) that causes hypoxia (lack of oxygen), dyspnoea (difficulty in breathing), tachypnoea (rapid breathing), cyanosis (lack of oxygen in the blood), fever and hypotension.
• Akutno oštećenje pluća povezano s transfuzijom koje uzrokuje hipoksiju (nedostatak kisika), dispneju (otežano disanje), tahipneju (ubrzano disanje), cijanozu (nedostatak kisika u krvi), vrućicu i nizak krvni tlak.
In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.
U slučaju nuspojava potrebno je ili smanjiti brzinu primjene infuzije ili zaustaviti infuziju.
• Patients with Secondary Immunodeficiency Syndromes (SID) with severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l (group 2)
• bolesnici sa sindromima sekundarne imunodeficijencije s teškim ili ponavljajućim infekcijama, neučinkovitim antimikrobnim liječenjem te ili s dokazanim izostankom odgovora specifičnog protutijela (engl. proven specific antibody failure, PSAF)* ili s razinom IgG-a u serumu < 4 g/l (skupina 2).
● influenza like illness
● bolest nalik gripi
● conjunctivitis (inflammation of the conjuntiva of the eyes)
● konjunktivitis (upala konjunktive oka)
The maximum IgA content is 100 micrograms/ml.
Maksimalni sadržaj IgA iznosi 100 mikrograma/ml.
• Increase in serum creatinine level (a test which measures your kidney function) and/or acute renal failure (which signs are low back pain, fatigue, decrease in the amount of urine).
• povećanje razine serumskog kreatinina (test koji mjeri funkciju bubrega) i/ili akutno zatajenje bubrega (čiji su znakovi bol u donjem dijelu leđa, umor, smanjena količina mokraće)
2.0 g/kg should be administered as a single dose.
Dozu od 2,0 g/kg treba primijeniti jednokratno.
Cerebrospinal fluid studies are frequently positive with pleocytosis up to several thousand cells per mm3, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dl. AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment.
Pleocitoza do nekoliko tisuća stanica po mm3 pretežno granulocitne loze i povišene razine proteina do nekoliko stotina mg/dl često su prisutni u cerebrospinalnoj tekućini.
For patients experiencing adverse reactions, it is advisable to reduce the infusion rate in subsequent infusions and limit the maximum rate to 0.04 ml/kg/min or administer IVIg at a 5% concentration (see section 4.4).
U bolesnika kod kojih se javljaju nuspojave preporuča se smanjiti brzinu infuzije pri sljedećim primjenama i ograničiti maksimalnu brzinu na 0,04 ml/kg/min ili primijeniti i.v. Ig u koncentraciji od 5% (vidjeti dio 4.4).
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A and parvovirus B19 viruses.
Poduzete mjere se smatraju učinkovitima za viruse s ovojnicom kao što su virus ljudske imunodeficijencije (HIV), hepatitis B virus i hepatitis C virus te za viruse bez ovojnice kao što su hepatitis A virus i parvovirus B19.
The maximum IgA content is 50 micrograms/ml.
Maksimalni sadržaj IgA iznosi 50 mikrograma/ml.
Acne, Alopecia, Ecchymosis, Erythema, Hyperhidrosis, Palmar erythema, Purpura
Učestalost po infuziji tkiva akne, alopecija, ekhimoza, eritem, hiperhidroza, palmarni eritem, purpura manje često
• hyperhidrosis (excessive sweating)
• hiperhidroza (prekomjerno znojenje)
Patients with a kidney problem
Bolesnici s bubrežnim problemima
Can Guasc, 2 - Parets del Vallès 08150 Barcelona - Spain
Can Guasc, 2 - Parets del Vallès 08150 Barcelona
What Flebogamma DIF looks like and contents of the pack
Kako Flebogamma DIF izgleda i sadržaj pakiranja
What Flebogamma DIF is and what it is used for
Što je Flebogamma DIF i za što se koristi
● tachycardia (acceleration of the heart activity)
● tahikardija (ubrzani rad srca)
Flebogamma DIF contains sorbitol
Flebogamma DIF sadrži sorbitol
• (rarely) a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration
hemolitičku anemiju koja zahtijeva transfuziju • (rijetko) iznenadni pad krvnog tlaka i, u izoliranim slučajevima, anafilaktički šok čak i kada bolesnik nije pokazao preosjetljivost kod prethodne primjene
Three clinical trials were performed with Flebogamma DIF, one for replacement therapy in patients with primary immunodeficiency (in both adults and in children above 6 years) and two for immunomodulation, in patients with immune thrombocytopenic purpura (one in adult patients and another in both adults and in children between 3 and 16 years).
Provedena su tri klinička ispitivanja s Flebogamma DIF-om; jedno za nadomjesnu terapiju u bolesnika s primarnom imunodeficijencijom (u odraslih i djece starije od 6 godina) i dva ispitivanja za imunomodulaciju u bolesnika s imunološkom trompocitopeničnom purpurom (jedno u odraslih bolesnika i drugo u odraslih i djece u dobi između 3 i 16 godina).
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. Do not store above 30 ºC.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici i pakiranju iza oznake „Rok valjanosti“ ili EXP.
Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolaemic patients, and patients with diseases which increase blood viscosity).
Potrebna je pozornost u propisivanju i primjeni i.v. infuzije Ig u pretilih bolesnika i u bolesnika s postojećim čimbenicima rizika za trombotske događaje (poodmakla životna dob, visoki tlak, šećerna bolest, anamneza krvožilnih bolesti ili trombotskih epizoda, bolesnici sa stečenim ili naslijeđenim trombofilnim poremećajima, bolesnici s duljim razdobljima imobilizacije, bolesnici s teškom hipovolemijom te bolesnici s bolestima koje povećavaju viskoznost krvi).
● haematemesis (vomiting blood)
● hematemeza (povraćanje krvi)
Three clinical trials were performed with Flebogamma DIF, two for replacement therapy in patients with primary immunodeficiency (one in both adults and in children above 10 years and another in children between 2 to 16 years) and another for immunomodulation in adult patients with immune thrombocytopenic purpura.
Provedena su tri klinička ispitivanja s Flebogamma DIF-om; dva za nadomjesnu terapiju u bolesnika s primarnom imunodeficijencijom (jedno u odraslih i djece starije od 10 godina, a drugo u djece u dobi između 2 i 16 godina) i jedno ispitivanje za imunomodulaciju u odraslih bolesnika s imunološkom trompocitopeničnom purpurom.
PHARMACEUTICAL FORM AND CONTENTS Solution for infusion.
OBLIK I SADRŽAJ Otopina za infuziju.
While reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products containing various excipients such as sucrose, glucose and maltose, those containing sucrose as a stabiliser accounted for a disproportionate share of the total number.
Ig lijekova koji sadržavaju razne pomoćne tvari kao što su saharoza, glukoza i maltoza, oni koji sadržavaju saharozu kao stabilizator odgovorni su za neproporcionalni udio u ukupnom broju slučajeva.
Adverse reactions may occur more frequently - in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion - in patients with an untreated infection or underlying chronic inflammation
Nuspojave se mogu razviti češće - u bolesnika koji prvi put prime normalni ljudski imunoglobulin ili, u rijetkim slučajevima, kada se s lijeka s ljudskim normalnim imunoglobulinom prijeđe na neki drugi lijek ili kada je od prethodne infuzije prošlo dugo razdoblje
Therefore, IVIg recipients must be monitored for and IVIg infusion must be immediately stopped in case of pulmonary adverse reactions.
Stoga je bolesnike koji primaju i.v. Ig potrebno pratiti, a infuziju odmah zaustaviti u slučaju plućnih nuspojava.
These are used to treat conditions where the body's defence system against disease is not working properly.
Ovi se lijekovi koriste u terapiji raznih poremećaja rada obrambenog sustava tijela.
Maintenance dose: 1 g/kg every 2 to 4 weeks or 2 g/kg every 4 to 8 weeks.
Doza održavanja: 1 g/kg svaka 2 do 4 tjedna ili 2 g/kg svakih 4 do 8 tjedana.
Certain adverse reactions (e.g. headache, flushing, chills, myalgia, wheezing, tachycardia, lower back pain, nausea, and hypotension) may be related to the rate of infusion.
Određene nuspojave (npr. glavobolja, navale crvenila, zimica, mialgija, piskanje, tahikardija, bol u donjem dijelu leđa, mučnina i hipotenzija) mogu biti povezane s brzinom infuzije.